

Amendments to the Specification:

Please amend the specification as follows:

Please add the following paragraph as the first paragraph of the specification:

This application is a national stage entry under 35 U.S.C. § 371 of PCT patent application no. 99/07935 filed on June 22, 2000, which claims priority to French patent application no. FR99/07935, filed on June 22, 1999.

Please insert the following section heading on page 7 of the specification before the paragraph starting with “The object of the present invention is therefore polypeptide designated as ICBP90 ...”:

BRIEF SUMMARY OF THE INVENTION

Please insert the following paragraphs on page 8 of the specification before the paragraph starting with “It should be understood ...”:

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Figure 1 illustrates the expression of protein ICBP90 in HeLa cells (tumor cells) and in pulmonary fibroblasts in primary culture (non-tumoral cells).

Figure 2 illustrates immunoprecipitation of the endogenous protein.

Figure 3 illustrates nuclear localization of the endogenous protein.

Figure 4 illustrates expression of endogenous ICBP59 in proliferating cells.

Figure 5 illustrates expression of ICBP-59 in diverse human tissues.

Figure 6 illustrates nucleotide sequence of ICBP90 (nucleotide sequence SEQ ID NO. 1).

Figure 7 illustrates protein sequence of ICBP90 (amino acid sequence SEQ ID NO. 2).

Figure 8 illustrates detection of ICBP90 in the sera of patients displaying elevated serum markers for solid tumors.

Figure 9 illustrates structural organization of the ICBP 90 gene.

Figure 10 illustrates analysis of the ICBP promoter.

Figure 11 illustrates Northern and Western blot analysis of the expression of ICBP90.

DETAILED DESCRIPTION OF INVENTION

Please replace the legend of figure 6 on page 37 of the specification with the following rewritten legend:

Figure 6: Nucleotide sequence of ICBP90 (nucleotide sequence SEQ ID NO. 1).

cDNA coding for ICBP90 (nucleotide SEQ ID NO. 1) measures 2379 bp. The portions of sequence indicated in bold are those that do not appear in the human EST database (human dbest). The other sequences exist in diverse EST:

From 1 to 325: EST n° AI083773,

From 367 to 865 EST n° AA811055,

From 940 to 1857 EST n° AA488755, EST n° AA129794, and EST n° AA354253.

Please replace the legend of figure 7 on page 37 of the specification with the following rewritten legend:

Figure 7: Protein sequence of ICBP90 (amino acid sequence SEQ ID NO. 2).

The amino acid sequence of ICBP90 (amino acid sequence SEQ ID NO. 2) was deduced of the nucleotide sequence from figure 6 (SEQ ID NO. 1). ICBP (amino acid sequence SEQ ID NO. 2) is composed of 793 residues and has a theoretical molecular weight of 89,758 kDa. The pKi is 7.7. The amino acids indicated in grey correspond to ICBP-59.

Please replace the paragraph starting on line 20, page 43, of the specification with the following rewritten paragraph:

These gel retardation experiments in acrylamide gels has given us evidence that the new 59 kDa human protein can specifically bind an ICB DNA sequence. We have called this protein ICBP-59 (aminoacid sequence aa 263 to 793 of the sequence SEQ ID NO. 2) (for inverted CCAAT Box Binding Protein of 59 kDa).